Overall, the aim of this review is to provide molecular insights on AR signaling in metastatic castration resistance prostate cancer (mCRPC) as well as current and future perspectives on drug development to adequately inhibit this key pathway and overcome potential resistance mechanisms to, finally, improve the patient survival. This evidence concerns the gene AR and prostate carcinoma.